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OBJECTIVE—Leptin therapy has been found to reverse hyper-
glycemia and prevent mortality in several rodent models of type
1 diabetes. Yet the mechanism of leptin-mediated reversal of
hyperglycemia has not been fully deﬁned. The liver is a key organ
regulating glucose metabolism and is also a target of leptin
action. Thus we hypothesized that exogenous leptin administered
to mice with streptozotocin (STZ)-induced diabetes reverses
hyperglycemia through direct action on hepatocytes.
RESEARCH DESIGN AND METHODS—After the induction of
diabetes in mice with a high dose of STZ, recombinant mouse
leptin was delivered at a supraphysiological dose for 14 days by
an osmotic pump implant. We characterized the effect of leptin
administration in C57Bl/6J mice with STZ-induced diabetes and
then examined whether leptin therapy could reverse STZ-induced
hyperglycemia in mice in which hepatic leptin signaling was
speciﬁcally disrupted.
RESULTS—Hyperleptinemia reversed hyperglycemia and hyper-
ketonemia in diabetic C57Bl/6J mice and dramatically improved
glucose tolerance. These effects were associated with reduced
plasma glucagon and growth hormone levels and dramatically
enhanced insulin sensitivity, without changes in glucose uptake
by skeletal muscle. Leptin therapy also ameliorated STZ-induced
hyperglycemia and hyperketonemia in mice with disrupted
hepatic leptin signaling to a similar extent as observed in wild-
type littermates with STZ-induced diabetes.
CONCLUSIONS—These observations reveal that hyperleptinemia
reverses the symptoms of STZ-induced diabetes in mice and that
this action does not require direct leptin signaling in the liver.
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S
ince the discovery of insulin in 1922 (1), insulin
therapy has been the predominant treatment for
type 1 diabetes. However, the adipocyte-derived
hormone leptin has been found to reverse hy-
perglycemia and prevent mortality when administered to
several rodent models of type 1 diabetes (2–7). Leptin has
well known glucose-lowering effects in leptin-deﬁcient
ob/ob mice, and has been established as an important
regulator of glucose metabolism. Yet it is surprising that
leptin can restore euglycemia in insulin-deﬁcient rodents,
and the mechanism underlying this effect is unclear.
Insulin-deﬁcient diabetes is associated with elevated
circulating glucagon levels, which contributes to hyper-
glycemia (8–11). Interestingly, Yu et al. (2) demonstrated
that exogenous leptin can reverse hyperglucagonemia in
rats with streptozotocin (STZ)-induced diabetes and in
NOD mice; this effect of leptin therapy may contribute to
the restoration of euglycemia in these animals. In addition
to hyperglucagonemia, insulin resistance is another com-
mon characteristic of untreated human and rodent insulin
deﬁciency (12–15). Exogenous leptin can improve insulin
sensitivity in rats with STZ-induced diabetes (4,15,16).
Therefore the insulin sensitizing effect of leptin may also
contribute to lowering blood glucose in type 1 diabetic
rodents.
The liver is a key organ that controls glucose ﬂux in
response to many metabolic cues and is a major regulator
of lipid metabolism and ketone body production. There-
fore disturbed hepatic nutrient metabolism is likely a
major contributor to hyperglycemia, dyslipidemia, and
hyperketonemia in insulin-deﬁcient diabetes. Attenuated
insulin action on the liver alone contributes to perturba-
tions in glucose homeostasis (17). Leptin has well-known
insulin-sensitizing effects on the liver (18–20), and the long
signaling leptin receptor isoform (LepRb) is expressed in
the liver and hepatic cell lines (19,21). Intriguingly, we and
others have found that direct action of leptin on hepa-
tocytes can modulate hepatic insulin action (18,20,22,23).
We hypothesized that in mice with STZ-induced di-
abetes, exogenous leptin may act directly on the liver to
lower blood glucose and reverse the metabolic con-
sequences of insulin-deﬁcient diabetes. Peripheral leptin
therapy in the STZ-diabetic mouse model has not yet been
examined; therefore, to test our hypothesis we ﬁrst char-
acterized the effect of hyperleptinemia on metabolism in
mice with STZ-induced diabetes. After this, we examined
whether direct leptin action on the liver is required for the
therapeutic effect of leptin therapy in insulin-deﬁcient di-
abetes by administering exogenous leptin to mice with
STZ-induced diabetes that have a hepatic-speciﬁc disrup-
tion of leptin signaling.
RESEARCH DESIGN AND METHODS
Animals. C57Bl/6J male mice were obtained from Jackson Laboratories (Bar
Harbor, ME). Mice with a tissue-speciﬁc disruption of leptin signaling (referred
to as Lepr
ﬂox/ﬂox Albcre) and their wild-type littermate controls (Lepr
ﬂox/ﬂox)
were generated as previously described (23). Mice were fed a chow diet (5015
Laboratory Diet) and were housed with a 12-h:12-h light-dark cycle with ad
libitum access to food and water. All procedures with animals were approved
by the University of British Columbia Animal Care Committee and carried out
in accordance with the Canadian Council on Animal Care guidelines.
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ORIGINAL ARTICLESTZ administration. Ten-week-old C57Bl/6J mice were administered 200
mg/kgSTZ(SigmaAldrich)(preparedinacetatebuffer,pH4.5)viaintraperitoneal
(i.p.) injection 5 days before implantation of mini-osmotic pumps (described
below). Nondiabetic control mice were treated with acetate buffer alone.
Lepr
ﬂox/ﬂox Albcre and Lepr
ﬂox/ﬂox mice (10–18 weeks old) were given 180 mg/kg
i.p. STZ 4 days before pump implantation.
Leptin therapy via mini-osmotic pumps. Unless speciﬁed otherwise, STZ-
leptin mice received 10 mg/day mouse recombinant leptin (National Hormone
and Peptide Program) prepared in PBS via Alzet 14-day pumps (DURECT)
implanted subcutaneously on day 0 (day 0 refers to the day that pumps were
ﬁrst implanted). STZ-saline and nondiabetic controls received pumps loaded
with PBS only.
Plasma analyte measurements. Body weight, blood glucose, and plasma
analytes were measured after a 4-h fast unless speciﬁed otherwise. Random-fed
samples were collected at 11:00 P.M., 5 h into the dark cycle. Blood glucose was
monitored via a One Touch Ultra Glucometer (Life Scan, Burnaby, Canada)
from the saphenous vein. Glucagon (Mouse Glucagon RIA; Millipore), free
fatty acids (HR Series NEFA HR[2] Kit; Wako Chemical), b-hydroxybutyrate
(b-Hydroxybutyrate LiquiColor Test; Stanbio), growth hormone (Rat/Mouse
Growth Hormone ELISA; Millipore), and total corticosterone (Corticosterone
ELISA; ALPCO) were measured in plasma. Plasma leptin, insulin (23), triglyc-
erides, and cholesterol (24) were measured as previously described. For
C57Bl/6J mice, plasma was obtained from blood collected via cardiac puncture
on day 14 unless speciﬁed otherwise. Plasma from STZ-treated Lepr
ﬂox/ﬂox
Albcre and Lepr
ﬂox/ﬂox mice was obtained from saphenous vein blood on day 9,
and pre-STZ samples were collected from the same mice on day 26. Insulin
tolerance tests and i.p. glucose tolerance tests (IPGTTs) were performed by
monitoring blood glucose after an i.p. injection of insulin (0.65 units/kg;
Novolin) or dextrose (1.5 g/kg, 30% solution; Fisher Scientiﬁc), respectively
at time = 0.
Glucose uptake measurements. Five days after pump implantation, in vivo
glucose uptake was assessed by intravenous ﬂash tail vein injection of 40
mCi/kg 2-deoxy-D-[
14C]glucose (PerkinElmer Life and Analytical Sciences,
Waltham, MA) with or without 0.3 units/kg insulin (Novolin; prepared in 10
mmol/L sodium citrate, 0.03% BSA) in 4-h fasted mice anesthetized with an
injectable cocktail of acepromazine (Atravet), midazolam (Versed), and fen-
tanyl (Hynorm). Mice were killed 20 min postinjection by cervical dislocation,
and the soleus muscle was isolated for measurement of deoxy-[
14C]glucose-6-
phosphate accumulation as previously described (25) and normalized to tissue
mass.
RT-PCR analysis of leptin receptor transcripts. Liver tissue was homog-
enized in TRIzol (Invitrogen) via tissue homogenizer (Tissue Tearor; Biospec
Products). RNA was extracted following manufacturer instructions, and 1 mg
of RNA was used for cDNA synthesis using an iScript cDNA Synthesis kit
(Bio-Rad). Primers used to amplify cDNA are described previously (23).
Statistical analysis. All data are represented as means 6 SEM, and signiﬁ-
cance was set at P # 0.05. Statistical analyses were done using a Student t test
unless otherwise stated.
RESULTS
Leptin therapy ameliorates hyperglycemia in mice
with STZ-induced diabetes. We ﬁrst characterized the
effects of leptin therapy on metabolic parameters in mice
with STZ-induced diabetes. C57Bl/6J mice with STZ-induced
diabetes were given 10 mg/day recombinant mouse leptin
(STZ-leptin) or saline (STZ-saline), delivered continuously
for 14 days by a subcutaneous osmotic pump, and were
also compared with mice that were injected with vehicle
only instead of STZ (nondiabetic). STZ administration
depleted 4-h fasted plasma leptin levels from 1.2 6 0.5 ng/mL
in nondiabetic controls to below the detection limit (,0.2
ng/mL) in STZ-saline mice (Fig. 1A). STZ-leptin mice were
hyperleptinemic, with an approximately sevenfold increase
in plasma leptin compared with nondiabetic controls. Lep-
tin levels on day 14 were not signiﬁcantly different from
values obtained on day 7. Seven days after initiation of
treatment, 4-h fasted blood glucose concentrations in STZ-
leptin mice were reduced to nondiabetic levels (6.1 6 0.7
mmol/L STZ-leptin, 8.0 6 0.2 mmol/L nondiabetic, 23.2 6 1.3
mmol/L STZ-saline; Fig. 1B) and remained signiﬁcantly
lower than STZ-saline controls for the duration of the study.
Interestingly, on day 7 blood glucose levels in STZ-leptin
mice were signiﬁcantly lower than nondiabetic controls
(P = 0.018). Although blood glucose levels rose in some
individual STZ-leptin mice on day 14, average blood glu-
cose was not signiﬁcantly different compared with non-
diabetic controls on day 14 (P = 0.16). We next examined
whether leptin therapy ameliorated hyperketonemia.
b-Hydroxybutyrate, a predominant ketone body, was dras-
tically elevated in plasma from 4-h fasted STZ-saline mice
compared with nondiabetic controls, an effect that was fully
reversed by leptin therapy (Fig. 1C). Because high doses
of leptin can reduce body weight in some rodent models,
we investigated whether leptin treatment exacerbated
weight loss in mice with STZ-induced diabetes. STZ ad-
ministration caused a steady decline in body weight
(Fig. 1D); however, STZ-leptin mice maintained similar
body weight throughout the study to their STZ-saline
controls.
Leptin therapy acutely restores euglycemia in mice
with STZ-induced diabetes. We next examined whether
the glucose-lowering effect of hyperleptinemia in insulin-
deﬁcient mice persisted after cessation of leptin therapy.
C57Bl/6J mice with STZ-induced diabetes were treated
with 5 mg/day recombinant leptin via 14-day osmotic pumps
(Fig. 2). Blood glucose gradually declined over the treat-
ment period, and hyperglycemia was ameliorated by day 14
of leptin therapy. Hyperglycemia rapidly returned in the
STZ-leptin group after pump removal. At this point, the
STZ-saline group had to be killed because of deteriorated
body condition. When leptin was readministered to STZ-
leptin mice at a dose of 24 mg/day with a second pump im-
plant, hyperglycemia resolved to a similar extent as observed
with the previous dose, but within just 3 days of treatment.
These data suggest the maintenance of euglycemia in this
model requires continuous leptin administration and that the
rate of glucose lowering via leptin administration may be
dose dependent.
Hyperleptinemia improves postprandial glucose metab-
olism in diabetic mice. We next investigated whether
glucose metabolism was improved in the postprandial
state. Random-fed blood glucose levels were 8.1 6 0.3
mmol/L in nondiabetic mice, whereas the majority of
STZ-saline mice had glucose levels above the limit of de-
tection (33.3 mmol/L). Random-fed blood glucose levels
in STZ-leptin mice were 23.9 6 3.3 mmol/L, indicating at
least an ;26% reduction in fed blood glucose compared
with STZ-saline mice (Fig. 3A). To examine this more
thoroughly we performed an IPGTT (Fig. 3B). STZ-saline
controls had poor glucose control after a glucose chal-
lenge, and this was markedly improved in STZ-leptin
mice. Surprisingly, glucose clearance in STZ-leptin mice
was similar to nondiabetic controls, demonstrating that
hyperleptinemia dramatically improves glucose metabolism
in the absorptive state.
Leptin therapy reverses STZ-induced dyslipidemia.
We next sought to determine whether hyperleptinemia
reversed dyslipidemia in mice with STZ-induced diabetes
by measuring 4-h fasted plasma lipids. STZ administration
increased triglyceride and cholesterol levels in STZ-saline
mice compared with nondiabetic controls, whereas free
fatty acids were unaltered by STZ (Fig. 4A–C). Leptin
(10 mg/day) markedly reduced plasma triglycerides, free
fatty acids, and cholesterol in mice with STZ-induced di-
abetes to levels signiﬁcantly lower than both STZ-saline
and nondiabetic controls. Collectively, these data indicate
that leptin can alleviate dyslipidemia in mice with STZ-
induced diabetes.
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hormone levels and improves insulin sensitivity in
mice with STZ-induced diabetes. Although it is apparent
that leptin mimics the effect of insulin on glucose metabo-
lism in mice with STZ-induced diabetes, the mechanism for
this is unclear. As previously reported (2), hyperleptinemia
may lower blood glucose in STZ-induced diabetes by alle-
viating the hyperglucagonemia associated with insulin de-
ﬁciency. Indeed, STZ-saline mice had an ;2.5-fold increase
in 4-h fasted plasma glucagon levels compared with non-
diabetic controls, whereas STZ-leptin mice had plasma
glucagon levels that were similar to nondiabetic controls
(Fig. 5A). Four-hour fasted plasma growth hormone was in-
creased ;28-fold in STZ-saline mice compared with nondia-
betic mice and, similar to glucagon, growth hormone levels
were markedly decreased in response to leptin therapy,
although remaining signiﬁcantly higher than nondiabetic
levels (Fig. 5B). In contrast, plasma corticosterone was
increased in mice with STZ-induced diabetes compared with
nondiabetic controls but was unaltered by leptin therapy
(Fig. 5C). Therefore, the leptin-mediated suppression of
growth hormone and glucagon in mice with STZ-induced
diabetes likely contributes to glucose lowering.
As expected, the majority of 4-h fasted STZ-saline and
STZ-leptin mice had plasma insulin levels that were below
detection limits (,0.025 ng/mL) even using an ultrasensi-
tive mouse insulin ELISA (Fig. 5D). However, using this
ultrasensitive assay, insulin levels were detectable in
most random-fed STZ-saline and STZ-leptin mice, albeit
at ;9a n d;7% that of random-fed nondiabetic controls,
respectively. Although these data conﬁrm that hyper-
leptinemia does not reverse diabetes by increasing insulin
concentrations, it is important to note that insulin is not
completely eliminated by STZ administration. In light of
this, we investigated whether augmented insulin sensitivity
may also contribute to the glucose-lowering effect of leptin
in mice with STZ-induced diabetes. Both the nondiabetic
and STZ-leptin groups exhibited a potent response to exog-
enous insulin, such that 10 min after insulin injection all
but one mouse in both groups had blood glucose levels
FIG. 1. Leptin therapy reverses hyperglycemia and hyperketonemia in diabetic C57Bl/6J mice. Four-hour fasted parameters in STZ-leptin–treated
(black), STZ-saline (white), and nondiabetic (gray) mice are shown. Mice received subcutaneous 14-day osmotic pump implants containing a 10 mg/day
dose of leptin or saline on day 0. A: Plasma leptin levels on day 7 and day 14 after pump implantation (n = 5). Day 7 samples were collected from the
saphenous vein. Leptin was undetectable in plasma samples from STZ-saline mice. B: Blood glucose (n =5 ) .C: b-Hydroxybutyrate levels on day
14 (n ‡4). D: Body weight (n =5 ) .B and D: Statistical analyses were performed by one-way ANOVA multiple comparison procedure with Holm-
Sidak post hoc testing (Sigma Stat, SYSTAT Software, Inc.). *P < 0.01 STZ-leptin vs. STZ-saline mice; †P < 0.01 STZ-leptin vs. nondiabetic mice;
‡P < 0.01 STZ-saline vs. nondiabetic mice. Data are expressed as means 6 SEM.
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glucose administration; thus only one time point for these
groups was collected (Fig. 5E). STZ-saline controls were
signiﬁcantly insulin resistant compared with nondiabetic
mice, since insulin administration resulted in only a ;19%
drop compared with an ;56% drop in blood glucose, re-
spectively, 10 min post–insulin injection (P =0 . 0 0 0 2 3 ) .R e -
markably, leptin-treated mice displayed an ;76% drop in
blood glucose 10 min after insulin injection and were sig-
niﬁcantly more insulin sensitive than both STZ-saline mice
(P = 0.00016) and nondiabetic controls (P = 0.019). These
data indicate that not only does 10 mg/day leptin reverse
the insulin resistance observed in mice with STZ-induced
diabetes but it also augments insulin sensitivity beyond
that of nondiabetic mice. Therefore, although insulin levels
are not altered, enhanced insulin action in response to
hyperleptinemia may contribute to glucose lowering in
rodents with STZ-induced diabetes.
To determine whether the improved insulin sensitivity
observed in STZ-leptin mice was a result of increased
glucose uptake, we evaluated tissue-speciﬁc glucose up-
take in vivo by intravenous ﬂash injection of 2-deoxy-
D-[
14C]glucose as described previously (25,26). Glucose
uptake in the soleus muscle was comparable in STZ-saline
and STZ-leptin mice (Fig. 5F). An intravenous insulin bolus
increased glucose uptake in the soleus relative to base-
line; however, insulin-stimulated glucose uptake was not
signiﬁcantly increased in STZ-leptin mice compared with
STZ-saline controls. Because of the extreme depletion of
adipose tissue in both STZ-saline and STZ-leptin mice,
glucose uptake in adipose could not be determined.
These observations suggest that glucose uptake in skel-
etal muscle and adipose is not sufﬁcient to account for
the enhanced insulin sensitivity and restored euglycemia
in STZ-leptin mice.
Generation of mice with a liver-speciﬁc attenuation
of leptin signaling. Because leptin signaling can have
a direct insulin-like and insulin-sensitizing effect on the
liver (18,20,22), we determined whether hepatic leptin
signaling was involved in mediating the therapeutic effects
of hyperleptinemia in rodents with STZ-induced diabetes.
To accomplish this, we used the Cre-lox approach to de-
termine whether hyperleptinemia can reverse STZ-induced
diabetes in mice with disrupted hepatic leptin signaling
(Lepr
ﬂox/ﬂox Albcre mice). Lepr
ﬂox/ﬂox Albcre mice are ho-
mozygous for a ﬂoxed leptin receptor allele (Lepr
ﬂox) and
express the Cre transgene under control of the albumin
promoter, which confers hepatocyte-speciﬁc recombina-
tion of Lepr
ﬂox (23,27). Recombination produces a mutated
allele (Lepr D17) with a truncated intracellular signaling do-
main that can no longer mediate leptin-induced JAK-STAT
signaling (28) (Fig. 6A). RT-PCR analysis for LepRb mRNA
from liver cDNA generated an amplicon similar in size to
the 343 base pair product expected from wild-type
LepRb transcript in Lepr
ﬂox/ﬂox controls; liver cDNA from
Lepr
ﬂox/ﬂox Albcre mice produced an amplicon consistent
FIG. 2. The effects of leptin on hyperglycemia in mice with STZ-induced
diabetes are acute. Four-hour fasted blood glucose in STZ-leptin
(black) and STZ-saline (white) mice (n = 7) is shown. C57BL/6J mice
given STZ on day 25 were subsequently treated with 5 mg/day leptin or
saline via subcutaneous 14-day osmotic pumps implanted on day 0.
Pumps were removed on day 14 after blood glucose measurement.
STZ-saline mice were killed on day 19 because of deteriorating body
condition. The STZ-leptin group received a 7-day osmotic pump implant
delivering 24 mg/day leptin on day 24. Statistical analyses were per-
formed with one-way ANOVA multiple comparison procedure with
Holm-Sidak post hoc testing. Data are expressed as means 6 SEM.
FIG. 3. Leptin improves postprandial glucose metabolism in mice with STZ-induced diabetes. A and B: Random-fed blood glucose on day 13 and i.p.
glucose tolerance on day 9 in STZ-leptin (black), STZ-saline (white), and nondiabetic (gray) mice are shown. A: All but one STZ-saline mouse had
a blood glucose concentration above the limit of detection and was assigned a value of 33.3 mmol/L (n =5 ) .B: Mice received an i.p. injection of
1.5 g/kg glucose at time 0 (n ‡4). C: Area under the curve values for the IPGTT. Data are expressed as means 6 SEM.
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D17 tran-
script (Fig. 6B). Thus, in the livers of Lepr
ﬂox/ﬂox Albcre
mice, the majority of leptin receptors no longer contain the
JAK-STAT signaling domain.
Hepatic leptin signaling is not required for the
therapeutic effect of leptin in STZ-induced diabetes.
To determine whether leptin therapy reverses STZ-induced
diabetes through direct action on the liver, age-matched
male Lepr
ﬂox/ﬂox Albcre mice and Lepr
ﬂox/ﬂox littermate
controls were ﬁrst administered STZ to induce a state of
insulin deﬁciency. Following development of hypergly-
cemia, both Lepr
ﬂox/ﬂox controls and Lepr
ﬂox/ﬂox Albcre
mice were divided into two groups, one group treated
with 10 mg/day leptin and the other with saline, delivered




similar body weight, blood glucose, and plasma leptin and
insulin levels, as previously described (23). STZ admin-
istration produced an ;10-fold reduction in mean plasma
leptin in both Lepr
ﬂox/ﬂox Albcre and Lepr
ﬂox/ﬂox mice,
respectively (Fig. 7A), and treatment with 10 mg/day
leptin increased plasma leptin levels by .19-fold in both
types of mice.
We then examined whether hyperleptinemia in Lepr
ﬂox/ﬂox
Albcre mice could lower blood glucose to the same extent
as in Lepr
ﬂox/ﬂox controls. After STZ administration, all
groups displayed a similar extent of hyperglycemia (Fig.
7B). STZ-saline–treated Lepr
ﬂox/ﬂox Albcre mice and STZ-
saline–treated littermate controls were severely hypergly-
cemic for the duration of the study, whereas Lepr
ﬂox/ﬂox
Albcre and Lepr
ﬂox/ﬂox mice treated with leptin showed
a marked reduction in fasting blood glucose. Interestingly,
leptin treatment was equally effective at alleviating hy-
perglycemia in mice with disrupted hepatic leptin signaling
as in their wild-type littermates (Fig. 7B). However, unlike
our studies in C57Bl/6J mice, a 10 mg/day dose of leptin
was not able to fully restore fasting blood glucose levels to
pre-STZ levels in Lepr
ﬂox/ﬂox mice; this may be explained
by differences in genetic background, which can alter
leptin-related phenotypes (29,30). Nevertheless, compar-
ing Lepr
ﬂox/ﬂox Albcre mice with littermates of identical
genetic background reveals that liver leptin signaling is not
required for the glucose-lowering action of leptin in STZ-
induced diabetes.
In addition to assessing the impact of attenuated hepatic
leptin signaling on the glucose-lowering action of leptin,
we also examined the impact on the ketone lowering ac-
tion of leptin. Pre-STZ plasma b-hydroxybutyrate levels
were signiﬁcantly elevated by ;10- and ;5-fold after STZ
administration in Lepr
ﬂox/ﬂox Albcre and Lepr
ﬂox/ﬂox mice,
respectively (Fig. 7C). Similar to C57Bl/6J mice, leptin
therapy reduced plasma b-hydroxybutyrate levels by ;85%
in Lepr
ﬂox/ﬂox controls to pre-STZ values. This effect was
even more pronounced in Lepr
ﬂox/ﬂox Albcre mice, which,
despite inactivated hepatic leptin signaling, exhibited
a ;96% reduction in plasma b-hydroxybutyrate levels in
response to leptin therapy. In fact, leptin therapy reduced
plasma b-hydroxybutyrate to levels that were signiﬁcantly
lower than pre-STZ values in the Lepr
ﬂox/ﬂox Albcre mice
(P = 0.022). Thus, leptin action on hyperketonemia does
not depend on hepatic leptin signaling.
Lepr
ﬂox/ﬂox Albcre mice and Lepr
ﬂox/ﬂox controls ad-
ministered STZ displayed a gradual decrease in body
weight, and all groups had similar body weights for the
duration of the study (Fig. 7D). STZ administration de-
creased 4-h fasted insulin levels to ;13 and ;10% of pre-
STZ levels in Lepr
ﬂox/ﬂox controls and Lepr
ﬂox/ﬂox Albcre
mice, respectively, and insulin levels were not restored by
leptin therapy (Fig. 7E). Thus, similar to C57Bl/6J mice, the
effects of leptin on glucose and ketone levels are not at-
tributable to changes in insulin levels or body weight.
Because hyperleptinemia could alleviate the symptoms
of insulin-deﬁcient diabetes in mice with disrupted hepatic
leptin signaling, we predicted that enhanced insulin sen-
sitivity would still be observed in these mice in response
to leptin therapy. To test this we performed insulin toler-
ance tests. Both Lepr
ﬂox/ﬂox Albcre and Lepr
ﬂox/ﬂox mice
with STZ-induced diabetes displayed signiﬁcantly enhanced
insulin sensitivity in response to leptin treatment compared
with their saline-treated counterparts (P = 0.00081 and P =
0.033, respectively; Fig. 7F). Therefore, hepatic leptin sig-
naling is not required for the augmentation of insulin action
by leptin therapy.
DISCUSSION
To investigate the mechanism of leptin action on glucose
homeostasis in type 1 diabetes, we examined the effect
of hyperleptinemia in mice with STZ-induced diabetes.
FIG. 4. Leptin reduces plasma lipid levels in mice with STZ-induced diabetes. Four-hour fasted plasma triglycerides (A), cholesterol (B), and
free fatty acids (C) in STZ-leptin (black), STZ-saline (white), and nondiabetic (gray) mice on day 14 (n ‡ 4) are shown. Data are expressed as
means 6 SEM.
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1418 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgFIG. 5. Leptin reduces plasma glucagon and growth hormone levels and enhances insulin action in mice with STZ-induced diabetes. Four-hour fasted
plasma glucagon (A), growth hormone (B), and corticosterone (C)o nd a y1 4( n ‡4) are shown. D: Four-hour fasted plasma insulin (day 7) and random-
fed plasma insulin (day 13) were measured in samples collected from the saphenous vein. Fasted insulin was undetectable in all but one mouse in
both the STZ-leptin and STZ-saline groups (n ‡4), whereas random-fed insulin was detectable in most STZ-induced mice tested (n ‡3). The limit of
detection (0.025 ng/mL) is shown as a broken line. E: Insulin tolerance test (day 4; n = 5). All but one mouse in both the STZ-leptin and nondiabetic
groups had to be rescued with exogenous glucose at 10 min after insulin injection. Statistical analyses were performed using Student t test on 10-min
values. F: Glucose uptake measured in soleus muscle collected 20 min after intravenous injection of 2-deoxy-D-[
14C]glucose with and without insulin
(n =3 –5). Glucose uptake was normalized to tissue weight. STZ-leptin (black), STZ-saline (white), and nondiabetic (gray) are shown. *P < 0.05 STZ-
leptin vs. STZ-saline mice; †P < 0.05 STZ-leptin vs. nondiabetic mice; ‡P < 0.05 STZ-saline vs. nondiabetic mice. Data are expressed as means 6 SEM.
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tone levels, reduced plasma lipids, and normalized glucose
tolerance in response to an IPGTT. These ﬁndings support
previous observations in insulin-deﬁcient rodents (2–5).
The mechanism responsible for the effects of leptin in an
insulin-deﬁcient state is unclear. Insulin deﬁciency causes
marked hyperphagia (31), and leptin replacement nor-
malizes food intake in rats with STZ-induced diabetes
(15,32). Therefore, suppression of hyperphagia could lower
blood glucose by reducing nutrient intake. However, pair-
feeding studies indicate that decreased food intake cannot
account for the restoration of euglycemia in leptin-treated
insulin-deﬁcient rodents (2–5). Despite the anorexogenic
actions of leptin, mice with STZ-induced diabetes treated
with leptin did not display reduced body weight. This has
been reported previously in insulin-deﬁcient rodents treated
with physiological and supraphysiological doses of leptin
(2,4,5,15); in fact, others have reported that over prolonged
treatment periods, weight loss was actually attenuated in
hyperleptinemic rodents with type 1 diabetes compared
with diabetic controls (2). Yet similar doses of leptin have
been found to reduce body weight in both nondiabetic
C57Bl/6J mice and ob/ob mice (33), indicating that the
weight-reducing effect of leptin may be context de-
pendent. Diabetic animals pair-fed to leptin-treated ani-
mals display pronounced weight loss compared with both
leptin-treated and untreated diabetic animals fed ad libi-
tum (4,5,15). Attenuated weight loss in leptin-treated di-
abetic animals may be because of the improved health of
the animals, which may counter the anorexogenic action
of leptin. Supporting this phenomenon, German et al. (15)
recently found that leptin replacement actually inhibits
an STZ-induced increase in energy expenditure. These
studies suggest that in the context of insulin-deﬁcient
diabetes, hyperleptinemia has an anabolic effect that
opposes the anorexogenic action of leptin.
In addition to conﬁrming that hyperleptinemia lowers
plasma glucagon levels in STZ-induced diabetes (2), the
current study reveals that leptin therapy alleviates the in-
crease in plasma growth hormone associated with un-
controlled diabetes. Chronically elevated growth hormone
levels can decrease insulin sensitivity in rodents and
humans (34,35). Therefore, leptin-mediated suppression of
growth hormone may contribute to the improvement in
whole body insulin sensitivity observed in STZ-leptin mice.
We postulate that reduced glucagon and growth hormone
levels along with enhanced insulin action may mediate the
restoration of euglycemia in leptin-treated animals with
STZ-induced diabetes. German et al. (15) recently dem-
onstrated that in rats with STZ-induced diabetes, a physi-
ological dose of leptin normalizes plasma glucagon and
reverses insulin resistance, yet does not restore euglycemia.
Our observations do not contradict these ﬁndings; here,
mice with STZ-induced diabetes treated with a supra-
physiological dose of leptin were more insulin sensitive than
nondiabetic controls, whereas German et al. (15) found that
rats with STZ-induced diabetes treated with a physiological
dose of leptin had similar insulin sensitivity to nondiabetic
controls. This suggests that to restore euglycemia in insulin-
deﬁcient diabetes, the dose of leptin must be high enough to
reach a threshold of insulin sensitivity that can compensate
for dramatically lowered insulin levels.
Despite enhanced whole body insulin sensitivity, glu-
cose uptake in skeletal muscle was not altered by leptin
therapy, indicating that leptin-induced changes in insulin
sensitivity are likely mediated through other target tissues.
This supports previous data that under basal conditions,
the rate of glucose disappearance in hyperleptinemic rats
with STZ-induced diabetes is not increased compared with
diabetic controls (4). Several lines of evidence point to the
liver as a primary tissue mediating the antidiabetic effects
of leptin; leptin-treated rats with STZ-induced diabetes
exhibit reduced glucose appearance rates and decreased
expression/activation of hepatic gluconeogenic factors
(2,4,5). Although leptin can modulate liver glucose me-
tabolism through direct hepatic leptin signaling (18,36), the
current study reveals that this pathway is not required for
leptin therapy to ameliorate STZ-induced hyperglycemia or
hyperketonemia, or to enhance insulin sensitivity. Although
it is possible that some hepatocytes retain expression of
functional leptin receptors that compensate for atten-
uated hepatic leptin signaling, RT-PCR analysis in-
dicated that wild-type LepRb expression is efﬁciently
knocked out in the liver of Lepr
ﬂox/ﬂox Albcre mice.
Furthermore, Lepr
ﬂox/ﬂoxAlbcre mice trended toward a more
potent response to hyperleptinemia in regard to plasma
b-hydroxybutyrate and blood glucose levels than wild-
type littermates, as opposed to an attenuated response.
Although direct action on the liver is not required for the
glucose-lowering action of leptin therapy, leptin-induced
effects on liver metabolism through the brain may be im-
portant. Reconstitution of leptin receptors in the hypo-
thalamus of leptin receptor–deﬁcient rats enhances the
inhibitory action of insulin on hepatic glucose production
(30). Furthermore, central delivery of leptin was found
by Hidaka et al. (5) to reverse hyperglycemia in rats with
STZ-induced diabetes, a ﬁnding that has now been conﬁrmed
by others (6,7,37); interestingly, central leptin therapy can
inhibit hepatic glucose production in rats with STZ-induced
diabetes (37). The effects of leptin on circulating factors
FIG. 6. The long form of the leptin receptor is truncated in livers of
Lepr
ﬂox/ﬂox Albcre mice. A: Schematic representation of Lepr
ﬂox and
Lepr
D17 alleles. B: RNA was extracted from livers of Lepr
ﬂox/ﬂox Albcre
mice and Lepr
ﬂox/ﬂox controls for use as a template for generating
cDNA (RT+). Reactions lacking reverse transcriptase were set up as
negative controls (RT2). The cDNA generated was PCR ampliﬁed using
primers indicated in A. These primers generate a 343 base pair ampli-
con for the Lepr
ﬂox transcript and a 267 base pair amplicon for the
Lepr
D17 transcript. Arrows on the left denote the migration of molec-
ular weight markers.
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ﬂox/ﬂox Albcre mice. Four-hour fasted parameters in Lepr
ﬂox/ﬂox Albcre and
Lepr
ﬂox/ﬂox mice that were STZ administered on day 24, and received subcutaneous 14-day osmotic pumps delivering 10 mg/day leptin or saline on day
0, are shown. A:P l a s m al e p t i n( n ‡4). B:B l o o dg l u c o s e( n ‡4). C:P l a s m ab-hydroxybutyrate (n ‡4). D:B o d yw e i g h t( n ‡4). E: Plasma insulin (n ‡4).
Only two STZ-leptin–treated Lepr
ﬂox/ﬂox Albcre mice had detectable levels of insulin. F: Insulin tolerance test on day 11 (n ‡3). Area under the curve
values are shown in the inset. A, C,a n dE: Pre-STZ (gray), STZ-saline (white), and STZ-leptin (black). B, D,a n dF: Lepr
ﬂox/ﬂox Albcre mice given STZ-
leptin (▼)o rS T Z - s a l i n e( ▽). Lepr
ﬂox/ﬂox controls given STZ-leptin (●) or STZ-saline (○)a r es h o w n .B and D: Statistical analyses were performed
using one-way ANOVA multiple comparison procedure with Holm-Sidak post hoc testing on values. *P < 0.0001 Lepr
ﬂox/ﬂox Albcre STZ-leptin vs. STZ-
saline mice; #P < 0.0001 Lepr
ﬂox/ﬂox STZ-leptin vs. STZ-saline mice. Data are expressed as means 6 SEM.
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to the therapeutic action of leptin. By decreasing free fatty
acid levels, possibly through increased lipid oxidation in
adipose tissue (38), hyperleptinemia may enhance hepatic
insulin sensitivity (39). Furthermore, the suppression of
glucagon and growth hormone likely reduces hepatic glu-
cose output in STZ-induced diabetes. Therefore, direct
and/or indirect leptin action on other tissues including
adipocytes and pancreatic a-cells may also be important
for the therapeutic action of leptin (40–42). Although the
b-cell is a key target of leptin (24), it is unlikely to mediate
the therapeutic action of leptin after STZ-mediated b-cell
depletion. The inhibitory effect of leptin on insulin secretion
(24,43) would not beneﬁt insulin-deﬁcient rodents, and
hyperleptinemia does not appreciably alter insulin levels
or b-cell mass in rodents with type 1 diabetes (2). Eluci-
dating the direct target tissues, and the intracellular path-
ways required for the glucose-lowering effects of leptin in
type 1 diabetes, will provide important insight into both
physiological and therapeutic mechanisms of leptin action.
An important consideration for the use of leptin as a
therapeutic for type 1 diabetes will be the immune mod-
ulating actions of leptin. Treatment of young, prediabetic
NOD mice with leptin accelerates the onset of insulitis and
diabetes (44). Moreover, insulitis and T-effector cell acti-
vation is suppressed in NOD mice with a naturally occurring
loss-of-function mutation in the leptin receptor (45,46). In
contrast, hyperleptinemia has been found to prevent the
onset of virally induced autoimmune diabetes in the BBDR
rat (47). Therefore, the potential proautoimmune effects of
leptin therapy in patients with type 1 diabetes must be
thoroughly investigated.
Based on observations from the current study and by
others, leptin may prove to be a promising therapy for
type 1 diabetes. Interestingly, some of the metabolic dis-
turbances associated with insulin deﬁciency may be caused
by the hypoleptinemia in uncontrolled insulin-deﬁcient
diabetes (32,48). In rats with STZ-induced diabetes, leptin
replacement reverses insulin resistance, hyperglucagonemia,
and hyperphagia (15,32). Thus, leptin replacement may
prove a rational therapy for type 1 diabetes. Further-
more, leptin therapy may have some advantages over
insulin therapy. We observed that in Lepr
ﬂox/ﬂox mice, al-
though hyperglycemia was only partially rescued with
leptin therapy, hyperketonemia was completely reversed.
The disappearance of ketone bodies in response to leptin
may be due to leptin action on systemic free fatty acids
or changes in hepatic metabolic pathways. This is pro-
vocative since resolution of diabetic ketoacidosis with
continuous insulin administration in human patients is
reported to occur after hyperglycemia is reversed (49,50).
A potential pitfall of leptin administration in conjunction
with insulin is increased risk of hypoglycemia. In our
studies, a single dose of insulin that modestly lowered
blood glucose in untreated diabetic animals caused rapid
and severe hypoglycemia in leptin-treated animals. Thus,
although leptin in combination with insulin may dramatically
improve treatment for patients with type 1 diabetes, further
studies must more rigorously assess the increased risk of
hypoglycemia.
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